---
aliases: >-
  /news/iqvia-selected-to-accelerate-clinical-development-of-vyvgart-efgartigimod-alfa-fcab-by-argenx-se
archetype: press-release
author:
  - Radhika Narayanan
basePath: /news/
breadcrumbLinks:
  - /
  - /news/
  - ''
breadcrumbs:
  - Home
  - News
  - >-
    IQVIA selected to accelerate clinical development of VYVGART™ (efgartigimod
    alfa fcab) by argenx SE
categories:
  - 'Events Taxonomies: Clinical Documentation'
  - 'Medigy: Media (Press) Release'
categorySlug:
  - 'events taxonomies: clinical documentation'
  - 'medigy: media (press) release'
categoryUrl:
  - topic/events-taxonomies-clinical-documentation
  - topic/medigy-media-press-release
categoryLabel:
  - Clinical Documentation
  - Media (Press) Release
contentCategories: netspective-medigy-news-curated-content
institution:
  - id: 2206
    title: IQVIA Inc.
    description: >-
      IQVIA is a world leader in using data, technology, advanced analytics, and
      expertise to help customers drive healthcare forward. Together with the
      companies we serve, we are enabling a more modern and effective healthcare
      system and creating breakthrough solutions that transform business and
      patient outcomes.


      The healthcare environment is rapidly evolving. Scientific advances are
      accelerating, and technology is enabling new levels of progress. Today,
      the industry has more data and information at its fingertips than ever
      before.


      IQVIA Connected Intelligence™ is our approach to helping customers drive
      healthcare forward in this challenging, fast-paced environment.  By making
      intelligent connections between our customers’ needs, our capabilities,
      and the evolving healthcare ecosystem, we help customers accelerate
      results, improve patient outcomes, and unleash new opportunities.
    alias: /profile /offeror/institution/iqvia-inc
    slug: iqvia-inc
    url: /profile/offeror/institution/iqvia-inc
    logo: 2206-logo.JPEG
offering: null
layOut: news-press-release-single
date: '2022-06-01'
description: >-
  RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA (NYSE:IQV) announced an
  agreement today with argenx SE. The multi-year contract covers a unique
  collaboration for the development of new indicatio
favIconImage: null
featuredImage: null
featuredPdf: null
htmlMetaData:
  author: null
  description: null
  generator: null
  viewport: null
  articlemodified_time: null
  articlepublished_time: null
  msvalidate.01: null
  ogdescription: null
  ogimage: null
  ogsite_name: null
  ogtitle: null
  ogtype: null
  ogupdated_time: null
  ogurl: null
  yandex-verification: null
  robots: null
  fbapp_id: null
  oglocale: null
  fbadmins: null
  articlepublisher: null
  google-site-verification: null
  keywords: null
id: 13309
identifier: News
lastMod: '2022-06-01T10:47:34.394271Z'
link:
  brand: iqvia.com
  href: >-
    https://www.iqvia.com/newsroom/2022/03/iqvia-selected-to-accelerate-clinical-development-of-vyvgart-efgartigimod-alfa-fcab-by-argenx-se
  original: >-
    https://www.iqvia.com/newsroom/2022/03/iqvia-selected-to-accelerate-clinical-development-of-vyvgart-efgartigimod-alfa-fcab-by-argenx-se
href: >-
  https://www.iqvia.com/newsroom/2022/03/iqvia-selected-to-accelerate-clinical-development-of-vyvgart-efgartigimod-alfa-fcab-by-argenx-se
original: >-
  https://www.iqvia.com/newsroom/2022/03/iqvia-selected-to-accelerate-clinical-development-of-vyvgart-efgartigimod-alfa-fcab-by-argenx-se
mastHead: NEWS
mdName: ec6bc616-2a8c-5de9-8d29-bd1d5ee9aea5.md
openGraphMetaData:
  ogdescription: null
  ogtitle: null
  ogurl: null
  ogimage: null
  ogsite_name: null
  ogtype: null
  ogupdated_time: null
  ogimageheight: null
openProjectCustomFields:
  cleanUrl: >-
    https://www.iqvia.com/newsroom/2022/03/iqvia-selected-to-accelerate-clinical-development-of-vyvgart-efgartigimod-alfa-fcab-by-argenx-se
  medigyTopics:
    - 'Events Taxonomies: Clinical Documentation'
    - 'Medigy: Media (Press) Release'
  sourceUrl: >-
    https://www.iqvia.com/newsroom/2022/03/iqvia-selected-to-accelerate-clinical-development-of-vyvgart-efgartigimod-alfa-fcab-by-argenx-se
openProjectWorkPackageType: Press Release
searchCategory: News
slug: >-
  iqvia-iqvia-selected-to-accelerate-clinical-development-of-vyvgart-efgartigimod-alfa-fcab-by-argenx-se
source: open-project-curations
status: ''
sub: brief
tags:
  - News
title: >-
  IQVIA selected to accelerate clinical development of VYVGART™ (efgartigimod
  alfa fcab) by argenx SE
via: ' '
insights_description: null
insights_name: null
viaLink: null
relatedOfferings:
  - label: Clinical Monitoring Solutions
    permalink: /offering/clinical-monitoring-solutions
    categories:
      - 'Events Taxonomies: Clinical Documentation'
      - 'Symplur: #eHealth'
      - 'Events Taxonomies: Ambient Clinical Intelligence'
    offeringId: 12932
twitterMetaData:
  twittercard: null
  twitterdescription: null
  twittertitle: null
  twitterimage: null
  twitterurl: null
---
<p>RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA (NYSE:IQV) announced an agreement today with argenx SE. The multi-year contract covers a unique collaboration for the development of new indications for VYVGART™ (efgartigimod alfa fcab), an FDA-approved neonatal Fc receptor blocker for the treatment of generalized myasthenia gravis in adult patients who have a specific antibody receptor.</p><p>While terms of the deal have not been disclosed, the collaboration will support clinical development, regulatory, commercial and real-world evidence strategy to accelerate the development of new indications for VYVGART.</p><p>“We are excited to be working with argenx in a comprehensive way to support the development of their promising new treatment,” said Alistair Grenfell, president, Europe, Middle East, Africa and South Asia for IQVIA. “IQVIA’s end-to-end support will speed the clinical development and the commercial launch of new indications that drive argenx’s success. Together, our partnership will create new opportunities to improve human health and bring new hope to patients and their families.”</p><p>IQVIA brings together deep scientific expertise with unique technology and analytics to enable life sciences companies such as argenx to accelerate the clinical development and commercialization of innovative products that improve patient lives.</p><p><strong>About IQVIA</strong></p><p>IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 79,000 employees, IQVIA conducts operations in more than 100 countries.</p><p>IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors, and scientific advances, in an effort to advance their path toward cures. To learn more, visit <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.iqvia.com&amp;esheet=52587425&amp;newsitemid=20220301005740&amp;lan=en-US&amp;anchor=www.iqvia.com&amp;index=1&amp;md5=b78aad2d39e698954e21bad7d1011783">www.iqvia.com</a>.</p><p>View source version on <a href="http://businesswire.com/">businesswire.com</a>: <a href="https://www.businesswire.com/news/home/20220301005740/en/">https://www.businesswire.com/news/home/20220301005740/en/</a>&nbsp;</p><p>Source: IQVIA</p>